Risk factors of trastuzumab-induced cardiotoxicity in breast cancer: A meta-analysis

BACKGROUND: Trastuzumab targets the human epidermal growth factor receptor 2 oncogene and in combination with first-line therapy results in significantly improved survival outcomes and has thus become standard of care in both adjuvant and metastatic settings. While it is estimated that 1% to 4% of p...

Descripción completa

Detalles Bibliográficos
Autores principales: Jawa, Zeeshan, Perez, Ruth M., Garlie, Lydia, Singh, Maharaj, Qamar, Rubina, Khandheria, Bijoy K., Jahangir, Arshad, Shi, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5591107/
https://www.ncbi.nlm.nih.gov/pubmed/27858859
http://dx.doi.org/10.1097/MD.0000000000005195

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5591107/
https://www.ncbi.nlm.nih.gov/pubmed/27858859
http://dx.doi.org/10.1097/MD.0000000000005195

Ejemplares similares